IMPALA-2 A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP) SAV006-05 Site 38
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Savara Inc.
Start Date
August 13, 2021
End Date
October 31, 2026
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Savara Inc.
Start Date
August 13, 2021
End Date
October 31, 2026